| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50cffe617e6ab69bc7c738375f9f8eb0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4756
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4712
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N37-18 |
| filingDate |
2005-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_85160d6d4aab0e67c7362bd8bbe66ed3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd9421d3a7fcff45bd316a3a604f3167 |
| publicationDate |
2011-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7862995-B2 |
| titleOfInvention |
Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| abstract |
The present invention relates to a panel of targeted therapy markers that can be used in assessing a particular subject's sensitivity to various therapeutic agents and cancer treatments as a means of prognosticating whether a treatment or use of a particular therapeutic agent will result in a clinically positive outcome. Cellular receptors, ligands to those receptors and molecules involved in the programmed cell death pathway are examples of targeted therapy markers that might be used in the present invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11008620-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11221340-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10668028-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010183593-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012122101-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10359425-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010221752-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010086948-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010070191-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11041866-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8435752-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016091493-A1 |
| priorityDate |
2004-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |